fda to reconsider tirzepatide reviews decision put Lilly's on shortage list Compounded Tirzepatide vs Mounjaro/Zepbound: 75%

That trust encourages patients to remain consistent long term

From date of order to delivery was only 4 days

On average, participants who took semaglutide saw a loss of about 15% of their body weight, around six times more than the placebo

These are consistent with the broader class of GLP-1-based therapies and include: Nausea the most commonly reported symptom, particularly during dose escalation Vomiting less frequent than nausea but reported, especially at higher doses Diarrhoea often transient and associated with early treatment phases Constipation some participants report alternating bowel habits Decreased appetite a desired pharmacological effect, though it can feel uncomfortable initially Belching and bloating related to slowed gastric emptying Additional effects reported with retatrutide or with medicines in the same class include: Injection-site reactions such as redness, itching, or mild discomfort at the injection site Headache and dizziness particularly during early treatment Small increases in heart rate modest elevations have been observed with GLP-1-based therapies